Pfizer beats profit estimates on heart disease drug, COVID vaccine sales

(Reuters) – Drugmaker Pfizer (SpadeWall Street’s assessments of Wall Street were beaten for the fourth quarter on Tuesday, which helped with the slightest fear of heavy sale of drugs and miserable vaccines.

The company has scored 63 cents per share for a period of three months, compared to the average score of 47 cents per share.

Pfizer is faced with investor pressure to show that last achievements and investments can return.

After the huge success of its UKats-12 products during the epidemic, drugs struggle to persuade the shareholders that it may be loss of potential income, which is expected soon with patent.

The company’s shares fell almost 8% last year, and the results increased by about 2% in the previous hours. They trade less than half of their value at the peak of Sovim.

During the fourth quarter, the total income amounted to $ 17.76 billion, compared to $ 17.36 billion estimates, according to LSEG.

(Report on Manas Mishra and Benga in New York in New York. Editing by Saumyadeb Chakrabarty)